Ally Financial received a Strong Buy rating at $55 from Raymond James, while EyePoint Pharmaceuticals had its target slashed 80% to $4.

The entities involved

• Ally Financial →

  American financial services company

  Nothing else this week.

• EyePoint Pharmaceuticals (United Kingdom) →

  company specialising in the application of microelectromechanical systems (MEMS) and nanotechnology to drug delivery

  • EyePoint Pharmaceuticals was listed on Nasdaq, accompanied by rating updates from TD Cowen (downgrade) and Jefferies (upgrade).Mon 06:52
  • Trump's pledge to unleash American oil and gas benefits certain stocks, impacting EyePoint Pharmaceuticals.Sun 07:17
• TD Cowen →

  American investment bank

  • Analyst downgraded Ag Growth International Inc. due to debt management risks.Mon 12:33
  • TD Cowen raised its price target and gave a buy rating for Travere Therapeutics, Inc., while various institutional investors bought into the company.Mon 10:36

Related events

• MarketBeat is discussing EyePoint Pharmaceuticals, a company based in the United Kingdom, as a high-risk investment target.Aug 17
• TD Cowen raised its price target on Exelixis shares on August 30, 2026.Aug 30
• Raymond James Financial and TD Cowen issued rating updates for GDS, alongside an insider transaction disclosure filed with the SEC.Sep 7